- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05835128
Assessment of Long-term Sequelae of Coronavirus Disease 2019 (COVID-19) Pneumonia With Chest CT and Pulmonary Function Tests
A Multicentric Prospective Study: Assessment of Pulmonary Long-term Sequelae of Coronavirus Disease 2019 (COVID-19) Pneumonia With Chest Computed Tomography and Pulmonary Function Tests
The goal of this prospective multicentric study is to evaluate the presence of long-term pulmonary sequelae in patients who had required hospitalization for treating COVID-19 pneumonia, trough chest CT and pulmonary function tests (PFT).
Secondly we would like to evaluate the possible correlation between the chest CT findings and pulmonary function tests pre-existing co-morbidities and type of therapy used during hospitalization.
Study Overview
Status
Detailed Description
The investigators will invite to participate in this study patients who had been hospitalized with positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , namely with positive reverse transcription polymerase chain reaction or positive rapid antigen test, and with respiratory insufficiency (at admission or developed during hospital stay), or with viral pneumonia documented with thorax x-ray or Chest CT, during the period between march 2020 and march 2022.
Patients who agree to participate and sign the informed consent will be enrolled in the study.
Participants will be evaluate in two different periods: approximately 4 to 6 months after hospital discharge and approximately 12 to 14 months after hospital discharge.
The first evaluation includes a physical examination at medical post-COVID-19 consultation, pulmonary function tests and reduced dose chest CT.
The second evaluation includes a physical examination at medical post-COVID-19 consultation, and will include reduced dose chest CT and pulmonary function tests only if there were significative findings on those exams on the first evaluation, or if there are any clinical significative findings at the present moment.
All the evaluations must respect the following time intervals: the pulmonary function tests and the chest CT will be done within a 6 week maximum interval of each other, and both of these examinations will be done within a 8 week maximum interval regarding the clinical evaluation.
Demographic and clinical data will be collected by qualified clinical study staff (i.e., by physicians who conduct the post-COVID-19 medical consultation) and the patient will given the EuroQol 5 Dimension 5 Level questionnaire (EQ-5D-3L) to assess the health status.
The reduced dose Chest CT will be obtained with the patient in a supine position and with breath-holding following inspiration, in a spiral acquisition mode with a 1 ,5 mm slice thickness and the images will be reviewed by four senior radiologist blinded to clinical and respiratory functional tests results.
The pulmonary function tests will be interpreted according to the American Thoracic Society and European Respiratory Society guidelines 2022. The parameters measured included the forced expiratory flow between 25% and 75% of forced vital capacity (FVC), forced expiratory volume (FEV1), FVC/FEV1, vital capacity, total lung capacity, residual volume and the diffusing capacity of lung for carbone monoxide (DLCO), DLCO/Alveolar Volume (AV).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Faro, Portugal, 8005
- Hospital de Faro (CHUA)
-
Portimão, Portugal, 8500-338
- Hospital de Portimâo (CHUA)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- at least 18 years old of age;
- positive SARS-CoV-2 reverse transcription-polymerase chain reaction on a nasopharyngeal and/or oropharyngeal swab or positive SARS-CoV-2 rapid antigen test
- hospitalization in one of two hospitals of our institution (university center) in consequence of SARS-CoV-2 related disease between march of 2020 and march of 2022 and having :
- respiratory insufficiency when admitted or developing after admission or image documented viral pneumonia ;
- at least one thorax x-ray or lung CT acquired during the hospitalization period
Exclusion Criteria:
- previous lung cancer
- previous intersticial lung disease
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of structural lung sequelae after COVID-19 pneumonia
Time Frame: 12 -14 months
|
evaluate the presence of lung structural sequelae with chest CT
|
12 -14 months
|
Prevalence of functional lung impairment after COVID-19 pneumonia
Time Frame: 12 -14 months
|
evaluate the presence of impaired PFT after COVID-19 pneumonia
|
12 -14 months
|
Association between chest CT findings and PFT impairment after COVID-19 pneumonia
Time Frame: 12-14 months
|
evaluate the possible correlation between the presence of pulmonary structural alterations on chest CT and the presence of impaired PFT
|
12-14 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of structural lung sequelae after COVID-19 pneumonia
Time Frame: 4-6 months
|
evaluate the presence of lung structural sequelae with chest CT
|
4-6 months
|
Prevalence of functional lung impairment after COVID-19 pneumonia
Time Frame: 4-6 months
|
evaluate the presence of impaired PFT after COVID-19 pneumonia
|
4-6 months
|
Association between chest CT findings and PFT impairment after COVID-19 pneumonia
Time Frame: 4-6 months
|
evaluate the possible correlation between the presence of pulmonary structural alterations on chest CT and the presence of impaired PFT
|
4-6 months
|
Association between chest CT findings after COVID-19 pneumonia and therapy used during hospitalization
Time Frame: 4-6 months
|
to evaluate if there is any association between the presence of lung structural sequelae on chest CT and the different treatments used during hospitalization (corticotherapy, oxygen therapy, mechanical ventilation)
|
4-6 months
|
Association between chest CT findings after COVID-19 pneumonia and therapy used during hospitalization
Time Frame: 12-14 months
|
to evaluate if there is any association between the presence of lung structural sequelae on chest CT and the different treatments used during hospitalization (corticotherapy, oxygen therapy, mechanical ventilation)
|
12-14 months
|
Association between chest CT findings after COVID-19 pneumonia and pre-existing co-morbidities
Time Frame: 4-6 months
|
to evaluate if there is any association between the presence of lung structural sequelae on chest CT and pre-existing co-morbidities (diabetes, asthma, hypertension, dyslipidaemia, obesity, chronic obstructive pulmonary disease, cigarette smoking, heart disease and kidney disease)
|
4-6 months
|
Association between chest CT findings after COVID-19 pneumonia and pre-existing co-morbidities
Time Frame: 12 -14 months
|
to evaluate if there is any association between the presence of lung structural sequelae on chest CT and pre-existing co-morbidities (diabetes, asthma, hypertension, dyslipidaemia, obesity,, chronic obstructive pulmonary disease, cigarette smoking, heart disease and kidney disease)
|
12 -14 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Mónica Diniz, MD, Unafilliated
- Principal Investigator: Castro Miguel, MD, Centro Hospitalar Universitário do Algarve/Polo de Portimão
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Coronavirus Infections
- COVID-19
- pneumonia
- Lung Diseases
- Respiratory Tract Infections
- Infections
- Chest CT
- Tomography
- prospective studies
- RNA virus infections
- Respiratory tract diseases
- Lung CT
- respiratory function tests
- Virus Disease
- follow-up studies
- Infections, Viral
- Reduced dose chest CT
- coronaviridae infections
- lung sequela
- multicentric studies
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Lung Diseases
- Disease Attributes
- COVID-19
- Coronavirus Infections
- Infections
- Communicable Diseases
- Respiratory Insufficiency
- Pneumonia
Other Study ID Numbers
- UAIF 96/2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Pneumonia
-
Ministry of Health, KuwaitUnknownPneumonia, Viral | Moderate COVID-19 Pneumonia, Severe COVID-19 PneumoniaKuwait
-
Institute of Vaccines and Medical Biologicals,...National Institute of Hygiene and Epidemiology, Vietnam; Hanoi Medical University and other collaboratorsCompletedPneumonia, Viral | COVID-19 Vaccine | COVID-19 Disease | SARS PneumoniaVietnam
-
Patrick RobinsonRecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute BronchitisUnited States
-
Mahidol UniversityThe Government Pharmaceutical OrganizationCompletedPneumonia, Viral | Covid-19 | SARS Pneumonia | Covid-19 VaccineThailand
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Fundacion Clinica Valle del LiliUniversidad Autonoma de OccidenteCompletedCOVID-19 Pneumonia | COVID-19 (Coronavirus Disease 2019)Colombia
-
Medical University of LodzRecruitingCOVID-19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionPoland
-
Texas Tech University Health Sciences Center, El...RecruitingPneumonia, Viral | COVID-19 Pneumonia | COVID-19 Respiratory InfectionUnited States
-
Administracion Nacional de Laboratorios e Institutos...RecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionArgentina
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionItaly